

CITATION REPORT

List of articles citing

Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds

DOI: 10.1002/minf.202000028

Molecular Informatics, 2020, 39, e2000028.

Source: <https://exaly.com/paper-pdf/76935403/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
344	Novel cyclohexanone compound as a potential ligand against SARS-CoV-2 main-protease. 2020 , 149, 104546		20
343	Potential therapeutic effect of turmeric contents against SARS-CoV-2 compared with experimental COVID-19 therapies: in silico study. 2020 , 1-14		16
342	Using Chou's 5-steps rule to study pharmacophore-based virtual screening of SARS-CoV-2 Mpro inhibitors. 2021 , 25, 1731-1744		4
341	Molecular basis of COVID-19 pathogenesis. 2020 , 89, 858-878		11
340	Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects. 2020 , 33, 108254		107
339	Investigating Potential Inhibitory Effect of (Cat's Claw) against the Main Protease 3CL of SARS-CoV-2 by Molecular Modeling. 2020 , 2020, 4932572		16
338	Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface. 2020 , 89, 107372		16
337	In silico exploration of small-molecule α -helix mimetics as inhibitors of SARS-COV-2 attachment to ACE2. 2020 , 1-12		3
336	Virtual screening, molecular dynamics and structure-activity relationship studies to identify potent approved drugs for Covid-19 treatment. 2021 , 39, 6231-6241		32
335	Consensus virtual screening of dark chemical matter and food chemicals uncover potential inhibitors of SARS-CoV-2 main protease.. 2020 , 10, 25089-25099		15
334	Computational discovery of small drug-like compounds as potential inhibitors of SARS-CoV-2 main protease. 2021 , 39, 5779-5791		14
333	SARS-CoV and SARS-CoV-2 main protease residue interaction networks change when bound to inhibitor N3. 2020 , 211, 107575		12
332	Learning from history: do not flatten the curve of antiviral research!. 2020 , 25, 1604-1613		10
331	Artificial Intelligence (AI) and Big Data for Coronavirus (COVID-19) Pandemic: A Survey on the State-of-the-Arts. 2020 , 8, 130820-130839		107
330	In silico molecular docking and molecular dynamic simulation of potential inhibitors of 3C-like main proteinase (3CLpro) from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) using selected african medicinal plants. 2020 , 1		7
329	Structure-based identification of potential SARS-CoV-2 main protease inhibitors. 2020 , 1-14		35
328	Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site. 2020 , 11, 5877		60

327	A new prediction approach of the COVID-19 virus pandemic behavior with a hybrid ensemble modular nonlinear autoregressive neural network. 2020 , 1-10	4
326	COVID-19: Advances in diagnostic tools, treatment strategies, and vaccine development. 2020 , 45, 1	24
325	Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease. 2020 , 1-12	12
324	In-silico drug repurposing for targeting SARS-CoV-2 main protease (M). 2020 , 1-8	14
323	In Silico Discovery of Antimicrobial Peptides as an Alternative to Control SARS-CoV-2. 2020 , 25,	8
322	A program to automate the discovery of drugs for West Nile and Dengue virus-programmatic screening of over a billion compounds on PubChem, generation of drug leads and automated modelling. 2020 , 1-9	3
321	Interactive Molecular Dynamics in Virtual Reality Is an Effective Tool for Flexible Substrate and Inhibitor Docking to the SARS-CoV-2 Main Protease. 2020 , 60, 5803-5814	16
320	Dissecting the Drug Development Strategies Against SARS-CoV-2 Through Diverse Computational Modeling Techniques. 2020 , 329	4
319	Coronavirus diseases 2019: Current biological situation and potential therapeutic perspective. 2020 , 886, 173447	20
318	Genomics insights of SARS-CoV-2 (COVID-19) into target-based drug discovery. 2020 , 29, 1-15	21
317	Repurposing Low-Molecular-Weight Drugs against the Main Protease of Severe Acute Respiratory Syndrome Coronavirus 2. 2020 , 11, 7267-7272	16
316	The Use of Methods of Computer-Aided Drug Discovery in the Development of Topoisomerase II Inhibitors: Applications and Future Directions. 2020 , 60, 3703-3721	10
315	High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2. 2020 , 25,	47
314	COVID-19 and SARS-CoV-2. Modeling the present, looking at the future. 2020 , 869, 1-51	90
313	In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. 2020 , 56, 106119	24
312	Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design. 2020 , 88, 107351	40
311	Potential Therapeutic Agents and Associated Bioassay Data for COVID-19 and Related Human Coronavirus Infections. 2020 , 3, 813-834	17
310	Systemic Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server. 2020 , 60, 5735-5745	14

309	Protein reliability analysis and virtual screening of natural inhibitors for SARS-CoV-2 main protease (M) through docking, molecular mechanic & dynamic, and ADMET profiling. 2021 , 39, 6810-6827	11
308	The Current Recommended Drugs and Strategies for the Treatment of Coronavirus Disease (COVID-19). 2020 , 16, 933-946	4
307	Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches. 2020 , 19, 4291-4315	36
306	Stopping the COVID-19 Pandemic: A Review on the Advances of Diagnosis, Treatment, and Control Measures. 2020 , 2020, 9121429	10
305	SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. 2020 , 19, 40	62
304	Drug repurposing approach to fight COVID-19. 2020 , 72, 1479-1508	165
303	Computer-Aided Analysis of Multiple SARS-CoV-2 Therapeutic Targets: Identification of Potent Molecules from African Medicinal Plants. 2020 , 2020, 1878410	5
302	An overview of COVID-19 with an emphasis on computational approach for its preventive intervention. 2020 , 10, 435	9
301	Identification of potential inhibitors of SARS-CoV-2 main protease and spike receptor from 10 important spices through structure-based virtual screening and molecular dynamic study. 2020 , 1-22	23
300	Impact of Early Pandemic Stage Mutations on Molecular Dynamics of SARS-CoV-2 M. 2020 , 60, 5080-5102	38
299	Ligand and structure-based virtual screening applied to the SARS-CoV-2 main protease: an repurposing study. 2020 , 12, 1815-1828	51
298	Artificial Intelligence for COVID-19 Drug Discovery and Vaccine Development. 2020 , 3, 65	80
297	Putative SARS-CoV-2 M Inhibitors from an In-House Library of Natural and Nature-Inspired Products: A Virtual Screening and Molecular Docking Study. 2020 , 25,	21
296	Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease. 2020 , 8,	61
295	Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19. 2020 , 7, 616341	38
294	Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2. 2020 , 8, 590263	12
293	COVID-19, microthromboses, inflammation, and platelet activating factor. 2020 , 46, 927-933	25
292	Supercomputer-Based Ensemble Docking Drug Discovery Pipeline with Application to Covid-19. 2020 , 60, 5832-5852	71

291	Emerging role of artificial intelligence in therapeutics for COVID-19: a systematic review. 2020 , 1-16		11
290	Emerging Molecular Prospective of SARS-CoV-2: Feasible Nanotechnology Based Detection and Inhibition. 2020 , 11, 2098		5
289	Targeting Neutrophils to Treat Acute Respiratory Distress Syndrome in Coronavirus Disease. 2020 , 11, 572009		35
288	Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 M.. 2020 , 10, 40264-40275		13
287	FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication. 2021 , 39, 3419-3427		60
286	A Chemographic Audit of anti-Coronavirus Structure-activity Information from Public Databases (ChEMBL). <i>Molecular Informatics</i> , 2020 , 39, e2000080	3.8	8
285	Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition. 2020 , 21,		79
284	Fight against novel coronavirus: A perspective of medicinal chemists. 2020 , 201, 112559		44
283	Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors. 2020 , 56, 106055		44
282	Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19. 2020 , 256, 117963		37
281	Potential inhibitors of the interaction between ACE2 and SARS-CoV-2 (RBD), to develop a drug. 2020 , 256, 117970		30
280	Repurposing cefuroxime for treatment of COVID-19: a scoping review of studies. 2021 , 39, 4547-4554		17
279	Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases. 2020 , 31, 511-526		33
278	Remdesivir (GS-5734) as a therapeutic option of 2019-nCoV main protease - approach. 2021 , 39, 4701-4714		29
277	In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus. 2020 , 25,		38
276	Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. 2020 , 1866, 165878		404
275	Discovering small-molecule therapeutics against SARS-CoV-2. 2020 , 25, 1535-1544		61
274	Multiple Ensemble Neural Network Models with Fuzzy Response Aggregation for Predicting COVID-19 Time Series: The Case of Mexico. 2020 , 8,		88

273	Possible SARS-coronavirus 2 inhibitor revealed by simulated molecular docking to viral main protease and host toll-like receptor. 2020 , 15, 359-368	29
272	Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19. 2021 , 25, 1665-1677	27
271	Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS-CoV2: An In Silico Analysis. 2020 , 10,	33
270	Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors. 2020 , 88, 107325	47
269	Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design. 2020 , 21,	93
268	On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges. 2020 , 10,	76
267	Origin, Potential Therapeutic Targets and Treatment for Coronavirus Disease (COVID-19). 2020 , 9,	40
266	COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. 2020 , 46, 306-308	67
265	D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19. 2020 , 10, 1239-1248	41
264	Boosting the arsenal against COVID-19 through computational drug repurposing. 2020 , 25, 946-948	38
263	Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies. 2021 , 78, 1501-1522	56
262	Insights on 3D Structures of Potential Drug-targeting Proteins of SARS-CoV-2: Application of Cavity Search and Molecular Docking. <i>Molecular Informatics</i> , 2021 , 40, e2000096	3.8 7
261	Potential influence of <i>Nagella sativa</i> (Black cumin) in reinforcing immune system: A hope to decelerate the COVID-19 pandemic. 2021 , 85, 153277	28
260	Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors. 2021 , 29, 115860	58
259	A review of COVID-19 biomarkers and drug targets: resources and tools. 2021 , 22, 701-713	12
258	Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review. 2021 , 106, 104490	52
257	Potential inhibitors of SARS-CoV-2: recent advances. 2021 , 29, 349-364	7
256	Potential SARS-CoV-2 main protease inhibitors. 2021 , 26, 804-816	52

255	Supercomputing Pipelines Search for Therapeutics Against COVID-19. 2021 , 23, 7-16	6
254	Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication. 2021 , 20, 49-59	12
253	Eine Strategie zur Ligandenselektion identifiziert chemische Sonden für die Markierung von SARS-CoV-2-Proteasen. 2021 , 133, 6874-6881	2
252	A Ligand Selection Strategy Identifies Chemical Probes Targeting the Proteases of SARS-CoV-2. 2021 , 60, 6799-6806	10
251	The COVID-19 Ontology. 2020 ,	7
250	In silico allicin induced S-thioallylation of SARS-CoV-2 main protease. 2021 , 42, 109-120	11
249	Therapeutics for COVID-19: from computation to practices-where we are, where we are heading to. 2021 , 25, 625-659	27
248	Applications of Artificial Intelligence (AI) Protecting from COVID-19 Pandemic: A Clinical and Socioeconomic Perspective. 2021 , 45-60	0
247	Deep Learning-Based Drug Screening for COVID-19 and Case Studies. 2021 , 631	0
246	The Use of Tools for the Toxicity Prediction of Potential Inhibitors of SARS-CoV-2. 2021 , 49, 22-32	2
245	IoT and AI for COVID-19 in Scalable Smart Cities. 2021 , 3-19	3
244	Computational analysis of dynamic allostery and control in the SARS-CoV-2 main protease. 2021 , 18, 20200591	17
243	Application of Docking for Lead Optimization. 2021 , 271-294	0
242	Drug Databases for Development of Therapeutics Against Coronaviruses. 2021 , 761	1
241	Application of AI Techniques for COVID-19 in IoT and Big Data Era: A Survey. 2021 , 175-211	5
240	Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies. 2021 , 1, 33-41	36
239	The Main Protease of SARS COV-2 and Its Specific Inhibitors. 2021 , 121-147	1
238	Role of Machine Learning Techniques to Tackle the COVID-19 Crisis: Systematic Review. 2021 , 9, e23811	43

237	Harnessing the Capability of CADD Methods in the Prediction of Anti-COVID Drug Likelihood. 2021 , 269-287	
236	Contribution of machine learning approaches in response to SARS-CoV-2 infection. 2021 , 23, 100526	13
235	Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study. 2021 , 52, 38-47	25
234	Artificial intelligence-driven drug repurposing and structural biology for SARS-CoV-2. 2021 , 2, 100042	1
233	Computational Determination of Potential Multiprotein Targeting Natural Compounds for Rational Drug Design Against SARS-COV-2. 2021 , 26,	16
232	SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development. 2021 , 14, 225-238	10
231	Targeting allosteric pockets of SARS-CoV-2 main protease M. 2021 , 1-16	4
230	A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening. 2021 , 24, 102021	18
229	Advances in de Novo Drug Design: From Conventional to Machine Learning Methods. 2021 , 22,	28
228	Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases. 2021 , 288, 5089-5121	13
227	New Insights Into Potential Benefits of Bioactive Compounds of Bee Products on COVID-19: A Review and Assessment of Recent Research. 2020 , 7, 618318	6
226	Phytochemicals of spp. as Potential Inhibitors of the SARS-CoV-2 Main Protease: Molecular Docking and Drug-Likeness Study. 2021 , 2021, 8814890	5
225	Promising phytochemicals of traditional Indian herbal steam inhalation therapy to combat COVID-19 - An in silico study. 2021 , 148, 111966	17
224	Docking and toxicity assessment of compounds as potential antiviral agents against SARS-CoV-2. 2021 , 33, 1-24	12
223	Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies. 2021 , 1-13	7
222	A Blueprint for High Affinity SARS-CoV-2 Mpro Inhibitors from Activity-Based Compound Library Screening Guided by Analysis of Protein Dynamics. 2021 , 4, 1079-1095	15
221	Potential inhibitors interacting in Neuropilin-1 to develop an adjuvant drug against COVID-19, by molecular docking. 2021 , 33, 116040	10
220	High-throughput virtual laboratory for drug discovery using massive datasets. 2021 , 35, 452-468	2

219	Virtual Screening and Molecular Design of Potential SARS-COV-2 Inhibitors. 2021 , 76, 95-113	0
218	Artificial Intelligence-Aided Precision Medicine for COVID-19: Strategic Areas of Research and Development. 2021 , 23, e22453	8
217	drug designing for COVID-19: an approach of high-throughput virtual screening, molecular, and essential dynamics simulations. 2021 , 1-15	1
216	Dieckol and Its Derivatives as Potential Inhibitors of SARS-CoV-2 Spike Protein (UK Strain: VUI 202012/01): A Computational Study. 2021 , 19,	7
215	Drug repurposing to face Covid-19: Celastrol, a potential leading drug capable of inhibiting SARS-CoV-2 replication and induced inflammation.	
214	Computational Simulations Identified Marine-Derived Natural Bioactive Compounds as Replication Inhibitors of SARS-CoV-2. 2021 , 12, 647295	12
213	Detection of COVID-19 Disease in Chest X-Ray Images with capsul networks: application with cloud computing. 1-15	0
212	Potential drug targets of SARS-CoV-2: From genomics to therapeutics. 2021 , 177, 1-9	34
211	Investigation of angucycline compounds as potential drug candidates against SARS Cov-2 main protease using docking and molecular dynamic approaches. 2021 , 1	2
210	Docking Paradigm in Drug Design. 2021 , 21, 507-546	7
209	Structural dynamics of the Ecoronavirus Mpro protease ligand binding sites.	2
208	Novel 1,2,3-Triazole Derivatives as Potential Inhibitors against Covid-19 Main Protease: Synthesis, Characterization, Molecular Docking and DFT Studies. 2021 , 6, 3468-3486	12
207	Modeling the binding of protoporphyrin IX, verteporfin, and chlorin e6 to SARS-CoV-2 proteins. 2021 , 57, 1-9	5
206	COVID-19 Impacts, Diagnosis and Possible Therapeutic Techniques: A Comprehensive Review. 2021 , 27, 1170-1184	8
205	Can nutraceuticals assist treatment and improve covid-19 symptoms?. 2021 , 1-20	15
204	Rational design of potent anti-COVID-19 main protease drugs: An extensive multi-spectrum in silico approach. 2021 , 330, 115636	4
203	Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19. 2021 , 24, 716-728	22
202	The application of in silico experimental model in the assessment of ciprofloxacin and levofloxacin interaction with main SARS-CoV-2 targets: S-, E- and TMPRSS2 proteins, RNA-dependent RNA polymerase and papain-like protease (PLpro)-preliminary molecular docking analysis. 2021 , 73, 1765-1780	1

201	Target SARS-CoV-2: theoretical exploration on clinical suitability of certain drugs. 2021 , 1-8		0
200	Molecular dynamics analysis of N-acetyl-D-glucosamine against specific SARS-CoV-2's pathogenicity factors. 2021 , 16, e0252571		1
199	In silico Studies on the Interaction between Mpro and PLpro From SARS-CoV-2 and Ebselen, its Metabolites and Derivatives. <i>Molecular Informatics</i> , 2021 , 40, e2100028	3.8	15
198	Benchmarking the Ability of Common Docking Programs to Correctly Reproduce and Score Binding Modes in SARS-CoV-2 Protease Mpro. 2021 , 61, 2957-2966		13
197	Drug combination therapy for emerging viral diseases. 2021 , 26, 2367-2376		11
196	A hybrid in silico approach reveals novel inhibitors of multiple SARS-CoV-2 variants.		
195	Docking-based virtual screening studies aiming at the covalent inhibition of SARS-CoV-2 M by targeting the cysteine 145. 2021 , 92, 107463		3
194	Identification of non-covalent SARS-CoV-2 main protease inhibitors by a virtual screen of commercially available drug-like compounds. 2021 , 41, 127990		
193	A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2. 2021 , 22,		5
192	Dynamic Profiling of ECoronavirus 3CL M Protease Ligand-Binding Sites. 2021 , 61, 3058-3073		9
191	ssRNA Aptamers against the SARS-CoV-2 Main Protease: In Silico Design and Molecular Dynamics Simulation. 2021 , 22,		3
190	Plant-Based Phytochemical Screening by Targeting Main Protease of SARS-CoV-2 to Design Effective Potent Inhibitors. 2021 , 10,		18
189	New insights into the catalytic mechanism of the SARS-CoV-2 main protease: an ONIOM QM/MM approach. 2021 , 1		4
188	SARS-CoV-2 and its new variants: a comprehensive review on nanotechnological application insights into potential approaches. 2021 , 1-29		2
187	Advances in the computational landscape for repurposed drugs against COVID-19. 2021 , 26, 2800-2815		4
186	Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics. 2021 , 189, 114424		17
185	Rhizomes as a Natural Source of SARS-CoV-2 Mpro Inhibitors-Molecular Docking and In Vitro Study. 2021 , 14,		10
184	Strengths and Weaknesses of Docking Simulations in the SARS-CoV-2 Era: the Main Protease (Mpro) Case Study. 2021 , 61, 3758-3770		10

183	A machine learning regression model for the screening and design of potential SARS-CoV-2 protease inhibitors. 2021 , 10, 51	5
182	Drug repurposing combined with MM/PBSA based validation strategies towards MEK inhibitors screening. 2021 , 1-12	0
181	Accurate Estimation of Solvent Accessible Surface Area for Coarse-Grained Biomolecular Structures with Deep Learning. 2021 , 125, 9490-9498	0
180	Ensembling machine learning models to boost molecular affinity prediction. 2021 , 93, 107529	3
179	Near-physiological-temperature serial crystallography reveals conformations of SARS-CoV-2 main protease active site for improved drug repurposing. 2021 , 29, 1382-1396.e6	6
178	Identification of known drugs as potential SARS-CoV-2 Mpro inhibitors using ligand- and structure-based virtual screening. 2021 , 13, 1353-1366	5
177	Structural investigation of tetrahydropteridin analogues as selective PLK1 inhibitors for treating cancer through combined QSAR techniques, molecular docking, and molecular dynamics simulations. 2021 , 335, 116235	9
176	The identification of novel inhibitors of human angiotensin-converting enzyme 2 and main protease of Sars-Cov-2: A combination of methods for treatment of COVID-19. 2021 , 1237, 130409	4
175	Recent omics-based computational methods for COVID-19 drug discovery and repurposing. 2021 , 22,	3
174	Molecular Docking Analysis of the Phytochemicals from Tinospora Cordifolia as Potential Inhibitor Against Multi Targeted SARS-CoV-2 & Cytokine Storm. 2021 , 20, 559-580	0
173	Design and Evaluation of Bispidine-Based SARS-CoV-2 Main Protease Inhibitors.	2
172	Antiviral peptides against the main protease of SARS-CoV-2: A molecular docking and dynamics study.. 2021 , 14, 103315	12
171	Identifying compounds that prevent the binding of the SARS-CoV-2 S-protein to ACE2. 2021 , 136, 104719	1
170	Artificial Intelligence for COVID-19: A Systematic Review. 2021 , 8, 704256	7
169	The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance. 2021 , 1, 15	1
168	New 1,2,3-Triazole Scaffold Schiff Bases as Potential Anti-COVID-19: Design, Synthesis, DFT-Molecular Docking, and Cytotoxicity Aspects. 2021 , 9,	5
167	Design of ZnO-Drug Nanocarriers against the Main Protease of SARS-CoV-2 (COVID-19): An In Silico Assay. 2021 , 2, 257-266	0
166	Structural Understanding of SARS-CoV-2 Drug Targets, Active Site Contour Map Analysis and COVID-19 Therapeutics. 2021 ,	3

165	Hybrid Approach Reveals Novel Inhibitors of Multiple SARS-CoV-2 Variants. 2021 , 4, 1675-1688	2
164	Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review. 2021 , 224, 113705	35
163	Drug repurposing for COVID-19: Approaches, challenges and promising candidates. 2021 , 228, 107930	23
162	Evaluating anti-coronavirus activity of some phosphoramides and their influencing inhibitory factors using molecular docking, DFT, QSAR, and NCI-RDG studies. 2022 , 1248, 131481	6
161	Cheminformatics-Based Identification of Potential Novel Anti-SARS-CoV-2 Natural Compounds of African Origin. 2021 , 26,	14
160	Antiviral drug discovery: preparing for the next pandemic. 2021 , 50, 3647-3655	50
159	A critical overview of computational approaches employed for COVID-19 drug discovery. 2021 , 50, 9121-9151	36
158	Molecular Multi-target Approach on COVID-19 for Designing Novel Chemicals. 2021 , 179	1
157	Docking Simulations Exhibit Bortezomib and other Boron-containing Peptidomimetics as Potential Inhibitors of SARS-CoV-2 Main Protease. 2021 , 14, 279-288	5
156	In-silico strategies to combat COVID-19: A comprehensive review. 2021 , 37, 64-81	3
155	Recent progress in the development of potential drugs against SARS-CoV-2. 2021 , 2, 100057	0
154	Application of artificial intelligence and machine learning for COVID-19 drug discovery and vaccine design. 2021 , 22,	10
153	An analysis of Ibuprofen enantiomers in high concentrations of sodium chloride with SARS-CoV-2 main protease. 2021 , 1-12	4
152	1,2,4 triazolo[1,5-a] pyrimidin-7-ones as novel SARS-CoV-2 Main protease inhibitors: In silico screening and molecular dynamics simulation of potential COVID-19 drug candidates. 2020 , 267, 106478	11
151	Dual inhibition of SARS-CoV-2 spike and main protease through a repurposed drug, rutin. 2020 , 1-13	8
150	Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality. 2020 , 219,	9
149	How do we share data in COVID-19 research? A systematic review of COVID-19 datasets in PubMed Central Articles. 2021 , 22, 800-811	10
148	Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.	3

147	Computational Analysis of Dynamic Allostery and Control in the SARS-CoV-2 Main Protease.	5
146	The Role of Machine Learning Techniques to Tackle COVID-19 Crisis: A Systematic Review.	4
145	Near-Physiological-Temperature Serial Femtosecond X-ray Crystallography Reveals Novel Conformations of SARS-CoV-2 Main Protease Active Site for Improved Drug Repurposing.	2
144	Allosteric Hotspots in the Main Protease of SARS-CoV-2.	3
143	A blueprint for high affinity SARS-CoV-2 Mpro inhibitors from activity-based compound library screening guided by analysis of protein dynamics.	0
142	Screening marine algae metabolites as high-affinity inhibitors of SARS-CoV-2 main protease (3CLpro): an in silico analysis to identify novel drug candidates to combat COVID-19 pandemic. 2020 , 63, 79	14
141	COVID-19: molecular targets, drug repurposing and new avenues for drug discovery. 2020 , 115, e200254	11
140	Large-Scale Ligand-Based Virtual Screening for SARS-CoV-2 Inhibitors Using Deep Neural Networks.	25
139	Therapeutic Targets and Computational Approaches on Drug Development for COVID-19. 2020 , 20, 2210-2220	11
138	Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery. 2020 , 20, 1423-1433	26
137	Chinese Public's Attention to the COVID-19 Epidemic on Social Media: Observational Descriptive Study. 2020 , 22, e18825	128
136	Artificial Intelligence in the Fight Against COVID-19: Scoping Review. 2020 , 22, e20756	25
135	Artificial Intelligence for COVID-19: Rapid Review. 2020 , 22, e21476	41
134	Artificial Intelligence in the Fight Against COVID-19: Scoping Review (Preprint).	1
133	Artificial Intelligence for COVID-19: Rapid Review (Preprint).	1
132	Computational Models Identify Several FDA Approved or Experimental Drugs as Putative Agents Against SARS-CoV-2. 2020 ,	2
131	Supercomputer-Based Ensemble Docking Drug Discovery Pipeline with Application to Covid-19. 2020 ,	7
130	A Computational Approach to Explore the Interaction of Semisynthetic Nitrogenous Heterocyclic Compounds with the SARS-CoV-2 Main Protease. 2020 , 11,	4

129	Blocking Effect of Demethylzeylasteral on the Interaction between Human ACE2 Protein and SARS-CoV-2 RBD Protein Discovered Using SPR Technology. 2020 , 26,	10
128	An overview of potential therapeutic agents to treat COVID-19. 2020 , 14, 318-327	4
127	Potential COVID-19 papain-like protease PL inhibitors: repurposing FDA-approved drugs. 2020 , 8, e9965	30
126	High predictive QSAR models for predicting the SARS coronavirus main protease inhibition activity of ketone-based covalent inhibitors. 1	0
125	Michaelis-like complex of SARS-CoV-2 main protease visualized by room-temperature X-ray crystallography. 2021 , 8, 973-979	5
124	Evaluation of SARS-CoV-2 main protease and inhibitor interactions using dihedral angle distributions and radial distribution function. 2021 , 7, e08220	1
123	Tomatidine and Patchouli Alcohol as Inhibitors of SARS-CoV-2 Enzymes (3CLpro, PLpro and NSP15) by Molecular Docking and Molecular Dynamics Simulations. 2021 , 22,	12
122	De novo design of novel protease inhibitor candidates in the treatment of SARS-CoV-2 using deep learning, docking, and molecular dynamic simulations. 2021 , 139, 104967	19
121	DINC-COVID: A webserver for ensemble docking with flexible SARS-CoV-2 proteins. 2021 , 139, 104943	0
120	The Omic Insights on Unfolding Saga of COVID-19. 2021 , 12, 724914	0
119	Repurposing low molecular-weight drugs against the main protease of severe acute respiratory syndrome coronavirus 2.	
118	A Transferable Deep Learning Approach to Fast Screen Potent Antiviral Drugs against SARS-CoV-2.	
117	Role of Machine Learning Techniques to Tackle the COVID-19 Crisis: Systematic Review (Preprint).	
116	Natural Products-Based Drug Design against SARS-CoV-2 Mpro 3CLpro. 2021 , 22,	7
115	Structural, Electronic, and Electrostatic Determinants for Inhibitor Binding to Subsites S1 and S2 in SARS-CoV-2 Main Protease. 2021 , 64, 17366-17383	7
114	Deep Learning Driven Drug Discovery: Tackling Severe Acute Respiratory Syndrome Coronavirus 2. 2021 , 12, 739684	6
113	Identification of low micromolar SARS-CoV-2 Mpro inhibitors from hits identified by in silico screens.	2
112	Theoretical insights into the effect of halogenated substituent on the electronic structure and spectroscopic properties of the favipiravir tautomeric forms and its implications for the treatment of COVID-19.. 2021 , 11, 35228-35244	0

111	Artificial Intelligence, Machine Learning, and Deep Learning in Real-Life Drug Design Cases. 2022 , 2390, 383-407	2
110	Current Potential Therapeutic Approaches against SARS-CoV-2: A Review. 2021 , 9,	3
109	ReaxFF-based molecular dynamics simulation of the interaction between plasma ROS and the receptor-binding domain of the spike protein in the capsid protein of SARS-CoV-2.	1
108	In Silico Drug Repurposing of Penicillins to Target Main Protease Mpro of SARS-CoV-2. 2020 , 26, S52-S62	1
107	Molecular Docking of Novel 5-O-benzoylpinostrobin Derivatives as SARS-CoV-2 Main Protease Inhibitors. 2020 , 26, S63-S77	2
106	Potential Treatments for COVID-19; a Narrative Literature Review. 2020 , 8, e29	59
105	Potential SARS-COV preclinical (in vivo) compounds targeting COVID-19 main protease: a meta-analysis and molecular docking studies. 2020 , 24, 99-106	2
104	Structure-based Molecular Docking in the Identification of Novel Inhibitors Targeting SARS-CoV-2 Main Protease. 2021 ,	0
103	Both Baicalein and Gallocatechin Gallate Effectively Inhibit SARS-CoV-2 Replication by Targeting M and Sepsis in Mice. 2021 , 1	6
102	Global Pandemic as a Result of Severe Acute Respiratory Syndrome Coronavirus 2 Outbreak: A Biomedical Perspective.	
101	Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example. 2021 , 11, 591	0
100	DD-GUI: a Graphical User Interface for Deep Learning-Accelerated Virtual Screening of Large Chemical Libraries (Deep Docking). 2021 ,	2
99	Automated discovery of noncovalent inhibitors of SARS-CoV-2 main protease by consensus Deep Docking of 40 billion small molecules.. 2021 , 12, 15960-15974	6
98	A Practical Strategy for Exploring the Pharmacological Mechanism of Luteolin Against COVID-19/Asthma Comorbidity: Findings of System Pharmacology and Bioinformatics Analysis.. 2021 , 12, 769011	3
97	Compound screen identifies the small molecule Q34 as an inhibitor of SARS-CoV-2 infection.. 2021 , 103684	0
96	Molecular docking, molecular dynamics simulation and MM-GBSA studies of the activity of glycyrrhizin relevant substructures on SARS-CoV-2 RNA-dependent-RNA polymerase.. 2022 , 1-13	0
95	Innovative Ecosystem Model of Vaccine Lifecycle Management. 2022 , 8, 5	1
94	Discovery of compounds inhibiting SARS-COV-2 multi-targets.. 2022 , 1-16	0

93	Binding mechanism of inhibitors to SARS-CoV-2 main protease deciphered by multiple replica molecular dynamics simulations.. 2022 ,	6
92	Artificial intelligence-enabled virtual screening of ultra-large chemical libraries with deep docking.. 2022 ,	10
91	Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses.. 2022 ,	16
90	Investigating Novel Thiazolyl-Indazole Derivatives as Scaffolds for SARS-Cov-2 MPro Inhibitors. 2022 , 4, 100034	
89	Contribution of Deep-Learning Techniques Toward Fighting COVID-19: A Bibliometric Analysis of Scholarly Production During 2020.. 2022 , 10, 33281-33300	1
88	Pyrido[1,2-]purine: Design and Synthesis of Appropriate Inhibitory Candidates against the Main Protease of COVID-19.. 2022 ,	1
87	Complex machine learning model needs complex testing: Examining predictability of molecular binding affinity by a graph neural network.. 2022 ,	1
86	Non-covalent SARS-CoV-2 M inhibitors developed from in silico screen hits.. 2022 , 12, 2505	4
85	Targeting two potential sites of SARS-CoV-2 main protease through computational drug repurposing.. 2022 , 1-11	1
84	A Novel Deep Neural Network Technique for Drug-Target Interaction.. 2022 , 14,	0
83	Artificial Intelligence Technologies for COVID-19 De Novo Drug Design.. 2022 , 23,	1
82	Systematic Tracing of Susceptible Animals to SARS-CoV-2 by a Bioinformatics Framework.. 2022 , 13, 781770	0
81	Molecular insights to the binding interactions of APNS containing HIV-protease inhibitors against SARS-CoV-2 M: an approach towards drug repurposing.. 2022 , 1-14	0
80	Perceiving SARS-CoV-2 Mpro and PLpro dual inhibitors from pool of recognized antiviral compounds of endophytic microbes: an in silico simulation study.. 2022 , 1-25	2
79	Identification of potential antivirals against 3CLpro enzyme for the treatment of SARS-CoV-2: A multi-step virtual screening study.. 2022 , 1-30	0
78	Machine learning prediction of 3CL SARS-CoV-2 docking scores.. 2022 , 98, 107656	0
77	The Role of Molecular Modeling and Bioinformatics in Treating a Pandemic Disease: The Case of COVID-19. 2021 , 1, 216-234	0
76	A Comparison between Enrichment Optimization Algorithm (EOA)-Based and Docking-Based Virtual Screening.. 2021 , 23,	0

75	The transformational role of GPU computing and deep learning in drug discovery. 2022 , 4, 211-221	6
74	Data_Sheet_1.docx. 2020 ,	
73	Image_1.TIFF. 2020 ,	
72	Computer-aided identification of potential inhibitors against <i>Necator americanus</i> glutathione S-transferase 3. 2022 , 30, 100957	
71	Using Data to Identify Anticipated Learning Outcomes for New and Existing Curricula. 2022 , 29-47	
70	The Role of Big Data Analytics in Drug Discovery and Vaccine Development Against COVID-19. 2022 , 232-260	
69	Drug repurposing for SARS-CoV-2: a high-throughput molecular docking, molecular dynamics, machine learning, and DFT study.. 2022 , 1-23	0
68	Probing the Immune System Dynamics of the COVID-19 Disease for Vaccine Designing and Drug Repurposing Using Bioinformatics Tools. 2022 , 2, 344-371	1
67	A Review of Computational Approaches Targeting SARS-CoV-2 Main Protease to the Discovery of New Potential Antiviral Compounds.. 2022 ,	0
66	Computational Modeling of Supramolecular Metallo-organic Cages Challenges and Opportunities. 5806-5826	3
65	L-Proline Catalyzed Knoevenagel Condensation of Aldehydes with Active Methylene Compounds and Their Molecular Modeling Studies for Anti-SARS CoV-2 Potentials. 2022 , 18,	0
64	A Comprehensive Review of Artificial Intelligence in Prevention and Treatment of COVID-19 Pandemic.. 2022 , 13, 845305	
63	Role of Artificial Intelligence in Diagnosis of Infectious Diseases. 2022 , 115-133	
62	Discovery of novel Glutaminase allosteric inhibitors through drug repurposing and comparative MMGB/PBSA and molecular dynamics simulation. 2022 , 105669	1
61	Isolation and Characterization of <i>Werneria Chromene</i> and <i>Dihydroxyacidissimol</i> from <i>Burkillanthus malaccensis</i> (Ridl.) Swingle. 2022 , 11, 1388	0
60	In Silico Identification of Potential Inhibitors of the SARS-CoV-2 Nucleocapsid Through Molecular Docking-Based Drug Repurposing.	
59	Pre-exascale HPC approaches for molecular dynamics simulations. Covid-19 research: A use case.	0
58	Exploration of potential inhibitors for SARS-CoV-2 Mpro considering its mutants via structure-based drug design, molecular docking, MD simulations, MM/PBSA and DFT calculations.	1

57	Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2.	7
56	Targeting SARS-CoV-2 non-structural protein 13 via helicase-inhibitor-repurposing and non-structural protein 16 through pharmacophore-based screening.	1
55	When virtual screening yields to inactive drugs dealing with false theoretical-friends.	0
54	Natural products as a therapy to combat against SARS-CoV-2 virus infection. 2022 , 115-145	
53	Landscape determinants of infectivity and insights into vaccine development and effectiveness □ Novel Coronavirus. 2022 , 19,	
52	Therapeutic role of traditionally used Indian medicinal plants and spices in combating COVID-19 pandemic situation. 1-20	0
51	Allosteric hotspots in the main protease of SARS-CoV-2. 2022 , 167748	0
50	An agent-based transmission model of COVID-19 for re-opening policy design. 2022 , 105847	0
49	A comprehensive review of artificial intelligence and network based approaches to drug repurposing in Covid-19. 2022 , 153, 113350	2
48	Virtual screening of substances used in the treatment of SARS-CoV-2 infection and analysis of compounds with known action on structurally similar proteins from other viruses. 2022 , 153, 113432	1
47	Portability for GPU-accelerated molecular docking applications for cloud and HPC: can portable compiler directives provide performance across all platforms?. 2022 ,	0
46	Is the reductionist paradox an Achilles Heel of drug discovery?. 2022 , 36, 329-338	
45	Viral informatics: bioinformatics-based solution for managing viral infections.	1
44	QFFT quantum circuits for exact solutions of the black-hole singularity-mass schrödinger equations on quantum kerr- (A) ds galilean myersperr driven gravitational transformations in a lorentzian path integral for the anti-COVID-19 roccuffirnatm, roccuttirnaTM, and eplerotiffirnaTM drug designs. 2022 , 9,	0
43	Antiviral potential of diminazene aceturate against SARS-CoV-2 proteases using computational and in vitro approaches. 2022 , 367, 110161	2
42	Deep learning-based molecular dynamics simulation for structure-based drug design against SARS-CoV-2. 2022 , 20, 5014-5027	0
41	Multicriteria group decision making via generalized trapezoidal intuitionistic fuzzy number-based novel similarity measure and its application to diverse COVID-19 scenarios.	0
40	Adsorption of Selected Molecules on (TiO ₂) ₂₀ Nano-Clusters: A Density-Functional-Theory Study. 2022 , 2, 124-145	1

39	A computational insight on the inhibitory potential of 8-Hydroxydihydrosanguinarine (8-HDS), a pyridone containing analogue of sanguinarine, against SARS CoV2..	1
38	Pelargonium sidoides Root Extract: Simultaneous HPLC Separation, Determination, and Validation of Selected Biomolecules and Evaluation of SARS-CoV2 Inhibitory Activity. 2022 , 15, 1184	0
37	Visible Light-Promoted Green and Sustainable Approach for One-Pot Synthesis of 4,4-Bis(arylmethylene)bis(1H-pyrazol-5-ols), In Vitro Anticancer Activity, and Molecular Docking with Covid-19 Mpro. 2022 , 7, 34583-34598	0
36	Generation of new inhibitors of selected cytochrome P450 subtypesIn silico study. 2022 ,	0
35	Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CLpro. 2022 , 207, 105419	0
34	Computational Modeling of Protease Inhibitors for the Development of Drugs Against Coronaviruses. 2021 , 473-493	0
33	Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer. 2022 , 12, 1590	0
32	Deep learning in drug discovery: a futuristic modality to materialize the large datasets for cheminformatics. 1-16	0
31	Screening, Docking, and Molecular Dynamics Study of Natural Compounds as an Anti-HER2 for the Management of Breast Cancer. 2022 , 12, 1729	0
30	Structure and Computational Studies of New Sulfonamide Compound: {(4-nitrophenyl)sulfonyl}tryptophan. 2022 , 27, 7400	0
29	Using filters in virtual screening: A comprehensive guide to minimize errors and maximize efficiency. 2022 ,	0
28	Characterizing the ligand-binding affinity to SARS-CoV-2 Mpro via physics and knowledge based approaches.	0
27	In silico evaluation of the inhibitory potential of nucleocapsid inhibitors of SARS-CoV-2: a binding and energetic perspective. 1-11	1
26	Review of Developments in Combating COVID-19 by Vaccines, Inhibitors, Radiations, and Nonthermal Plasma. 2022 , 44, 5666-5690	1
25	Progress on COVID-19 Chemotherapeutics Discovery and Novel Technology. 2022 , 27, 8257	1
24	Pathfinder-Driven Chemical Space Exploration and Multiparameter Optimization in Tandem with Glide/IFD and QSAR-Based Active Learning Approach to Prioritize Design Ideas for FEP+ Calculations of SARS-CoV-2 PLpro Inhibitors. 2022 , 27, 8569	0
23	Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CLpro. 2022 , 23, 16011	1
22	Surely you are joking, Mr Docking!.	1

- 21 Pyridine derivatives complexes of Co (II) and Ni (II) 3-Bromobenzoates: Crystal Structure, in silico Anti-SARS-CoV-2 potential, Serum Albumin Binding Properties and Cytotoxicity. ○
- 20 Multi-ligand molecular docking, simulation, free energy calculations and wavelet analysis of the synergistic effects between natural compounds baicalein and cubebin for the inhibition of the main protease of SARS-CoV-2. **2023**, 121253 ○
- 19 Paving New Roads Using Allium sativum as a Repurposed Drug and Analyzing its Antiviral Action Using Artificial Intelligence Technology. **2023**, 21, ○
- 18 Natural product inhibitors as potential drug candidates against Alzheimer's disease: Structural-based drug design, molecular docking, molecular dynamic simulation experiments, and ADMET predictions. **2023**, 100, 100977 ○
- 17 Advances in the discovery of new chemotypes through ultra-large library docking. **2023**, 18, 303-313 ○
- 16 Discovery of Isojacareubin as a covalent inhibitor of SARS-CoV-2 main protease using structural and experimental approaches. **2023**, 95, ○
- 15 AI-accelerated protein-ligand docking for SARS-CoV-2 is 100-fold faster with no significant change in detection. **2023**, 13, ○
- 14 Role of SARS-CoV-2 Spike-Protein-Induced Activation of Microglia and Mast Cells in the Pathogenesis of Neuro-COVID. **2023**, 12, 688 1
- 13 Artificial Intelligence, Machine Learning, and Big Data for Ebola Virus Drug Discovery. **2023**, 16, 332 ○
- 12 Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. **2023**, 24, 4401 ○
- 11 Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery Genetics Alliance Perspective. **2023**, 66, 3664-3702 ○
- 10 Advances and critical assessment of machine learning techniques for prediction of docking scores. ○
- 9 Synthesis, molecular docking and dynamics studies of pyridazino[4,5-b]quinoxalin-1(2H)-ones as targeting main protease of COVID-19. 1-13 ○
- 8 Chemical Space Virtual Screening against Hard-to-Drug RNA Methyltransferases DNMT2 and NSUN6. **2023**, 24, 6109 ○
- 7 SARS-CoV2 billion-compound docking. **2023**, 10, ○
- 6 Discovery of Potential Inhibitors of SARS-CoV-2 Main Protease by a Transfer Learning Method. **2023**, 15, 891 ○
- 5 Outpatient medications associated with protection from COVID-19 hospitalization. **2023**, 18, e0282961 ○
- 4 The Impact of Supervised Learning Methods in Ultralarge High-Throughput Docking. ○

- 3 The role of machine learning in health policies during the COVID-19 pandemic and in long COVID management. 11, o
- 2 In-silico approaches for identification of compounds inhibiting SARS-CoV-2 3CL protease. **2023**, 18, e0284301 o
- 1 Computational approaches streamlining drug discovery. **2023**, 616, 673-685 o